Slide 1: Elevating the World's Wellbeing
Elevating the World’s Wellbeing
Slide 2: Forward-looking statement
Q12025 i Forward-looking statement This presentation contains certain forward-looking statements and opin- ions. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for example, contain wording su
Slide 3: Agenda
Q1 2025 Agenda Q1 in Short Business Updates Financial Results Strategy and Outlook Q&A Matthew Poulter Interim CFO
Slide 4: Q1 in Short
1.Q1 in Short
Slide 5: Driving Growth through Streamlined Operations and High-Margin Innovations
Q1 2025 Driving Growth through Streamlined Operations and High-Margin Innovations 3% 24% 4% €0.1m 31% Pro-forma revenue Year-on-Year recurring Q1 Net cash-flow Adjusted EBITDA margin Physitrack MRR growth growth revenue growth to positive generation €14.2m 25% €3.0m €0.4m 12% Lifecare Adjusted Adjus
Slide 6: Our two business lines positioned to capitalise on digital healthcare demand
Our two business lines have us well-positioned to capitalise on increasing digital healthcare demand and corporate wellbeing challenges. 23% Wellness One platform, all areas of employee wellbeing Technology for employers 77% Lifecare Seamless and efficient care solutions Technology for healthcare pr
Slide 7: Lifecare Quarterly update
Q1 2025 Lifecare Quarterly update Continued Strong Growth: Lifecare revenue grew 6% year-on-year, driven by a 24% MRR growth in the Physitrack product, with recurring revenue continuing to make up 99% of total revenue. 6% Churn Product Development & Innovation: In the quarter, a phased rollout of a
Slide 8: Wellness Quarterly update
Q1 2025 Decline in revenue due to pivot to SaaS focused model: Pro-forma revenue declined Wellness Quarterly update by 7% / €60k due to the pivot of Champion Health Nordic away from low margin product sales to a SaaS centric revenue stream alongside Champion Health in Q1 2024 including one-off upfro
Slide 9: Wellnow divestment
Q1 2025 Wellnow divestment Completed for €1 nominal consideration and €243k deferred earn-out based on 50% of forecast 2025-2026 profit Gain from discontinued operations of €78k recognised; made up of loss of €186k on disposal, transation costs of €120k, offset by Q125 contribution of €25k and write
Slide 10: Champion Health restructure
Q1 2025 Champion Health restructure
Slide 11: Financial Results
Q1 2025 Financial Results
Slide 12: Q1 Financial Highlights
Q1 2025 Q1 Financial Highlights Q125 Pro-forma Anualised revenue Q125 Adjusted Revenue EBITDA €3.6m 3% €14.2m 1% €1.1m -% (2024: €3.5m) (Q424 (pro- (2024 (pro- forma): €14.2m) forma): €1.1m) Q125 Subscription Q125 Adjusted Q125 Free- Revenue EBITDA less CAPEX Cashflow €12.0m 6% €0.4m 33% €0.1m 79% (
Slide 13: SaaS Metrics & Outlook
Q12025 —— SaaS Metrics & Outlook Annual revenue per license °°. O+ Net Revenue Retention ee = Key focus for sustainable growth Pricing power and customer value Future Transparency SaaS Gross margin Enhanced SaaS KPI reporting efficiently a SaaS business delivers its product Qi was transitional but e
Slide 14: Q1 Revenue story
Q1 2025 Q1 Revenue story Business unit performance Lifecare 6% Growth Stable retention Strong MRR Growth Wellness 7% decline in pro-forma revene Shift to SaaS model in Champion Health Nordics Decline leading to higher-quality recurring income in long term
Slide 15: Profitability
Q12025 Profitability Adjusted EBITDA and margin ‘= = é EBITDA less CAPEX by division 2025 qiz028
Slide 16: Cash and liquidity position
Q1 2025 Cash and liquidity position Free cash flow
Slide 17: AI in Finance – What we're doing now and where we're going
Q1 2025 AI in Finance – What we’re doing now and where were going
Slide 18: Balance sheet
Q1 2025 Balance sheet 31 31 March 2025 December 2024 Euros '000 Goodwill, intangibles and PPE 25,613 26,413 Cash and cash equivalents 303 723 Borrowings (4,232) (4,808) Trade and other receivables 2,493 2,992 Trade and other payables (2,815) (3,123) Deferred revenue (1,938) (2,011) Deferred tax (183
Slide 19: Strategy and Outlook
Strategy and Outlook
Slide 20: Our Unique Value Proposition
Our Unique Value Proposition Holistic offering, powered by top-of-the-line tech True product market fit Prices in relation to the market rather than growth expectations Catering to consumer trends Improved patient outcomes through more personalized, data-driven care Positioned to capitalize on growt
Slide 21: How it all comes together - Investing in Physitrack
How it all comes together - Investing in Physitrack Market outlook and position Focus Areas High-reaching financial goals Top-line growth Physitrack aims to achieve a doubling of revenue within the medium term, replacing Growing market supported by 1. Market growth dynamics the previous target set i
Slide 22: << od ie) =
<< od ie) =